Clinical Trial Update: KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia [Phase 2]

View source ↗

Summary

A Phase 2 multiple-dose study of KN057 in moderately severe to severe hemophilia has completed, with the update noting trial status rather than detailing result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• KN057

Snippet

Sponsor: Suzhou Alphamab Co., Ltd. | Conditions: Hemophilia | Phase 2 | Status: COMPLETED